Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

Annals of Internal Medicine

Volumn 130, Issue 10, 1999, Pages 800-809

  Gould, Michael K ^a   Dembitzer, Anne D ^a   Doyle, Ramona L ^b   Hastie, Trevor J ^b   Garber, Alan M ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPARINIZATION; HUMAN; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0032955744     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-10-199905180-00003     Document Type: Article

References (67)

1. Weitz Jl. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-98.
2. Duroux P. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost. 1991;65:251-6.
3. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-82.
4. Prandoni P, Leasing AW, Buller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-5.
5. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992;68:14-8.
6. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med. 1993;153:1541-6.
7. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72:186-90.
8. Levine M, Gent M, Hirsh J, Leclerc J, Andersen D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81.
9. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-7.
10. Fiessinger J, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76:195-9.
11. Luomanmaki K, Granqvist S, Hallert C, Jauro I, Ketola K, Kim HC, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996;240:85-92.
12. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997;337: 657-62.
13. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med. 1995;155:601-7.
14. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 100:269-77.
15. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 1994;309:299-304.
16. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep vein thrombosis. An updated meta-analysis. Drugs. 1996;52(Suppl 7):30-7.
17. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380-7.
18. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127:531-7.
19. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-12.
20. Lau J, Ioannidis P, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-6.
21. Jekel JF, Elmore J, Katz DL. Epidemiology, Biostatistics, and Preventive Medicine. Philadelphia: WB Saunders; 1997:95-7.
22. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics. 1986;42:311-23.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177-88.
24. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol. 1991;44:127-39.
25. Petitti D. Meta-Analysis, Decision-Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York: Oxford Univ Pr; 1994.
26. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol. 1995;48:45-57.
27. Begg C. Publication bias. In: Cooper H, Hedges L, eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation; 1994:399-409.
28. Rosenthal R. The "file drawer" problem and tolerance for null results Psychological Bulletin. 1979;86:638-41.
29. Philbrick JT, Becker DM. Calf deep venous thrombosis: A wolf in sheep's clothing? Arch Intern Med. 1988;148:2131-8.
30. Passman MA, Moneta GL, Taylor LM Jr, Edwards JM, Yeager RA, McConnell DB, et al. Pulmonary embolism is associated with the combination of isolated calf vein thrombosis and respiratory symptoms. J Vase Surg. 1997;25:39-45.
31. McCullagh P, Nelder J. Generalized Linear Models. 2d ed. London: Chapman and Hall; 1989.
32. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, et al. [A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Randomized study]. Presse Med. 1988;17:197-200.
33. Heilmann JJ. [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route A multicenter study]. Rev Med Interne. 1989;10:375-81.
34. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand J, Maurat J. Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis [Abstract] Thromb Haemost. 1987;58(Suppl): 120.
35. Fiessinger JN, Lopez Fernandez M, Gatterer E, Olsson CG. Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial [Abstract] Haemostasis. 1994;24(Suppl 1):44.
36. Luomanmaki K, Hallert C, Kim H. Low molecular weight heparin (Fragmin) once daily vs. continuous infusion of standard heparin in the treatment of DVT [Abstract]. Haemostasis. 1994;24(Suppl 1):247.
37. Vogel G, Machulik M. Efficacy and safety of a low molecular weight heparin (LMW-Heparin Sandoz) in patients with deep vein thrombosis [Abstract]. Thromb Haemost. 1987;58:120.
38. Suarez C, Gomez N, Casado L, Cajal ML, Frieras A, Serrano F, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in long-term treatment of venous thrombosis in patients over 60 years old [Abstract], Thromb Haemost. 1995;73:982.
39. Leizorovicz A. Efficacy and safety of low molecular weight heparin (enoxaparin) and unfractionated heparin in proximal deep vein thrombosis [Abstract]. Thromb Haemost. 1997;Suppl:290.
40. Spiro T. A multicenter clinical trial comparing once and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis [Abstract]. Thromb Haemost. 1997;Suppl:373-4.
41. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost. 1994;71:698-702
42. Fishman A, Altaras M, Klein Z, Aviram R, Beyth Y. Low molecular heparin (Enoxaparin) as an alternative treatment of acute deep venous thrombosis in gynecologic oncology patients. Eur J Gynaecol Oncol. 1996;17:365-7.
43. Holmstrom M, Berglund MC, Granqvist S, Bratt G, Tornebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res. 1992;67:49-55.
44. Huet Y, Gouault-Heilmann M. Low molecular weight heparin fraction PK 10169: a new therapeutic means for anticoagulant therapy? Haemostasis. 1986;16:165-72.
45. Huet Y, Janvier G, Bendriss PH, Winnock S, Dugrais G, Freyburger G, et al. Treatment of established venous thromboembolism with enoxaparin: preliminary report. Acta Chir Scand Suppl. 1990;556:116-20.
46. Janvier G, Winnock S, Dugrais G, Vallet A, Dardel E, Serise JM, et al. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis. 1987;17:49-58.
47. Janvier G, Freyburger G, Winnock S, Dugrais G, Boisseau M, Boissieras P. An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg. Haemostasis. 1991;21:161-8.
48. Kirchmaier CM, Lindhoff-Last E, Rubesam D, Scharrer I, Vigh Z, Mosch G, et al. Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin - results of a pilot study. Thromb Res. 1994;73: 337-48.
49. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J Intern Med. 1996;240:395-401.
50. Partsch H, Kechavarz B, Mostbeck A, Kohn H, Lipp C. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once-or twice-daily low-molecular-weight heparin J Vasc Surg. 1996;24:774-82.
51. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res. 1989;55:767-78.
52. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation. 1989;80:935-40.
53. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost. 1985;54:813-7.
54. Bratt GA, Tornebohm E, Johanson M, Aberg W, Granqvist S, Lockner D. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis. Acta Chir Scand Suppl. 1988;543:96-100.
55. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost. 1990;64:506-10.
56. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-12.
57. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59:639-50.
58. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis, 1986;2:30-7.
59. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:2337-43.
60. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis. 1986;2(16 Suppl):25-9.
61. Zanghi' M, Morici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Int Med Res. 1988;16:474-84.
62. Luttichau U, Palazzini E. Antithrombotic therapy in phlebopathies of lower limbs: a controlled study of low molecular weight heparin versus heparin calcium. Riv Eur Sci Med Farmacol. 1989;11:351-8.
63. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecutar-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997;337:663-9.
64. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation. 1992;85:1380-9.
65. Prandoni P, Vigo M, Cattelan AM, Ruol A. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis. 1990;1:220-3.
66. Wolf H, Encke A, Haas S, Welzel D. Comparison of the efficacy and safety of Sandoz low molecular weight heparin and unfractionated heparin: interim analysis of a multicenter trial. Semin Thromb Hemost. 1991;17:343-6.
67. Pineo G, Hull R, Raskob G, Brant R, Green D. Decreased mortality in cancer patients treated for proximal deep vein thrombosis with low-molecular-weight heparin as compared with unfractionated heparin [Abstract]. Thromb Haemost. 1997;Suppl:384.